IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Phase 1

Recruiting

• Conditions: Advanced Biliary Tract Cancer
• Interventions: Drug: IBI310; Drug: sintilimab

• Registration Number: NCT05653180
• Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Brief Summary

This research study is designed to establish whether the combination of IBI310 \& Sintilimab has efficacy in patients with advanced BTC

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-12-06
• Study First Submitted QC: 2022-12-13
• Study First Posted: 2022-12-16
• Status Verified: 2023-03
• Study Start: 2023-03-10
• Last Update Submitted: 2023-03-31
• Last Update Posted: 2023-04-03
• Primary Completion: 2023-12-31
• Study Completion: 2024-06-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. The subject must sign the written informed consent form, and can comply with the visits and related procedures specified in the protocol.
2. Aged ≥18 years.
3. Patients with unresectable or relapsed or metastatic advanced Biliary tract cancer,and diagnosed by histology/cytology (except carcinoma of ampulla).
4. Had progressed after receiving at least first-line systemic treatment (if a patient has progressed within 6 months after receiving systemic treatment during adjuvant chemotherapy or concurrent radiochemotherapy, she will be deemed to have received first-line treatment).
5. Patients who have never received any anti-PD-1, anti-PD-L1/L2 antibody, anti-CTLA-4 antibody, or other immunotherapy.
6. The subject must have at least one measurable lesion as the target lesion (according to RECIST V1.1). A measurable lesion in the radiation field from previous radiotherapy or local treatment, can also be chosen as the target lesion if confirmed progression.

Exclusion Criteria

1. Diagnosis of other malignant tumors within 5 years before the first administration, excluding radically cured skin basal cell carcinoma, skin squamous cell carcinoma, radically resected carcinoma in situ and/or thyroid papillary carcinoma.
2. Patients who have previously received organ or bone marrow transplantation.
3. Patients with acute or chronic active hepatitis B or C infection, hepatitis B virus (HBV) DNA> 2000 IU/ml or 104 copies/ml; hepatitis C virus (HCV) antibody positive and HCV-RNA >103 copies/ml;. Patients with acute or chronic active hepatitis B or C infection who have received nucleotide antiviral therapy and are below the above standards can be selected.
4. Uncontrollable hypertension, systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg after best medical treatment, history of hypertensive crisis or hypertensive encephalopathy.
5. Pleural effusion, ascites, and pericardial effusion with clinical symptoms or requiring drainage , patients who only shows with a few pleural effusion, ascites, and pericardial effusion by imaging and with no clinical symptoms can be selected.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
IBI310+ sintilimab	IBI310	All Subjects will be treated with : Sintilimab 200mg IV Q3W continuously and IBI310 2mg/kg IV single dose, 3 weeks later, IBI310 maintenance dose is 1mg/kg IV Q6W until progression (treatment duration up to 24 months).
IBI310+ sintilimab	sintilimab	All Subjects will be treated with : Sintilimab 200mg IV Q3W continuously and IBI310 2mg/kg IV single dose, 3 weeks later, IBI310 maintenance dose is 1mg/kg IV Q6W until progression (treatment duration up to 24 months).

Primary Outcome Measures

Name	Time	Method
Objective response rate (ORR)	up to 24 months	Investigator evaluated ORR per RECIST V1.1

Secondary Outcome Measures

Name	Time	Method
progression free survival, PFS	up to 24 months	PFS is defined as the time from first treatment to the date of the first documented tumor progression as determined by the investigator (per RECIST 1.1), or death due to any cause.
duration of response, DoR	up to 24 months	Defined as the time from the first documented objective response to the first documented progressive disease or death of any cause, whichever occurs first;
Overall Survival,OS	up to 24 months	OS is defined as the time from enrollment to the date of death.
disease control rate, DCR	up to 24 months	Defined as the proportion of patients whose best response is CR, PR, and stable disease (SD) non-CR/non-PD

Trial Locations

Locations (1)

Hunan cancer Hospital; 🇨🇳 Changsha, Hunan, China